Q-omics provides the consensus-scored DESI2 profile across patient tissues and cancer cell-line models. DESI2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DESI2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, DESI2 RNA expression shows 20,730 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where DESI2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DESI2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DESI2 survival associations across molecular data types. DESI2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DESI2 RNA expression–survival associations across cancer types. High DESI2 expression shows unfavorable associations in ACC, MESO, KIRP, KICH, UVM and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DESI2 RNA expression.
This table summarizes DESI2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DESI2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DESI2 shows higher tumor expression in HNSC, KIRP, KIRC, LIHC, COAD and STAD. The HNSC box plot shows higher DESI2 RNA expression in tumor versus normal tissue (log2 FC = +1.330, t-test p < 0.001).
This table shows molecular features associated with DESI2 in patient tissues and cancer cell lines. In patient samples, DESI2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DESI2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
